Business Description
Kura Oncology Inc
NAICS : 325414
SIC : 2836
ISIN : US50127T1097
Total Employee Number:
260Description
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 23.93 | |||||
Equity-to-Asset | 0.17 | |||||
Debt-to-Equity | 0.23 | |||||
Debt-to-EBITDA | -0.08 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -1.97 | |||||
Beneish M-Score | -4.62 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -16 | |||||
3-Year EPS without NRI Growth Rate | -16.1 | |||||
3-Year FCF Growth Rate | 21.3 | |||||
3-Year Book Growth Rate | -31.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 15.23 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 58.3 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 36.76 | |||||
9-Day RSI | 49.45 | |||||
14-Day RSI | 54.01 | |||||
3-1 Month Momentum % | 3.78 | |||||
6-1 Month Momentum % | -1.74 | |||||
12-1 Month Momentum % | 44.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.15 | |||||
Quick Ratio | 6.14 | |||||
Cash Ratio | 5.72 | |||||
Days Inventory | 874.89 | |||||
Days Sales Outstanding | 46.24 | |||||
Days Payable | 6420.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.7 | |||||
Shareholder Yield % | -0.35 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 99.63 | |||||
Operating Margin % | -443.54 | |||||
Net Margin % | -411.19 | |||||
EBITDA Margin % | -407.43 | |||||
FCF Margin % | -117.9 | |||||
OCF Margin % | -108.86 | |||||
ROE % | -123.31 | |||||
ROA % | -42.49 | |||||
ROIC % | -355.89 | |||||
3-Year ROIIC % | -205.13 | |||||
ROC (Joel Greenblatt) % | -2182.36 | |||||
ROCE % | -50.01 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 13.41 | |||||
PB Ratio | 8.94 | |||||
Price-to-Tangible-Book | 8.94 | |||||
EV-to-EBIT | -1.41 | |||||
EV-to-Forward-EBIT | -1.35 | |||||
EV-to-EBITDA | -1.41 | |||||
EV-to-Forward-EBITDA | -1.35 | |||||
EV-to-Revenue | 5.75 | |||||
EV-to-Forward-Revenue | 4.3 | |||||
EV-to-FCF | -4.88 | |||||
| Price-to-Net-Current-Asset-Value | 12.25 | |||||
| Price-to-Net-Cash | 26.6 | |||||
Earnings Yield (Greenblatt) % | -70.92 | |||||
FCF Yield % | -8.72 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KURA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kura Oncology Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 71.639 | ||
| EPS (TTM) ($) | -3.35 | ||
| Beta | 1.2658 | ||
| 3-Year Sharpe Ratio | 0.21 | ||
| 3-Year Sortino Ratio | 0.36 | ||
| Volatility % | 50.64 | ||
| 14-Day RSI | 54.01 | ||
| 14-Day ATR ($) | 0.559686 | ||
| 20-Day SMA ($) | 10.67575 | ||
| 12-1 Month Momentum % | 44.11 | ||
| 52-Week Range ($) | 5.45 - 12.49 | ||
| Shares Outstanding (Mil) | 88.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kura Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kura Oncology Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 08:00 | In 114 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 113 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 16:30 | In 25 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 24 days | ||
| EHA Virtual Investor | 2026-06-12 08:00 | 8.86 (+1.72%) | ||
| General meeting for 2026 | 2026-06-04 08:30 | 8.66 (-3.30%) | ||
| TD Cowen 7th Annual Oncology Innovation Summit | 2026-05-26 13:30 | 11.25 (+1.17%) | ||
| Guidance call for 2026 | 2026-05-13 18:00 | 9.68 (+1.68%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 16:30 | 9.51 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 9.51 (+0.00%) |
Show
Entries
Kura Oncology Inc Frequently Asked Questions
What is Kura Oncology Inc(KURA)'s stock price today?
The current price of KURA is $10.91. The 52 week high of KURA is $12.49 and 52 week low is $5.45.
When is next earnings date of Kura Oncology Inc(KURA)?
The next earnings date of Kura Oncology Inc(KURA) is 2026-08-07 Est..
Does Kura Oncology Inc(KURA) pay dividends? If so, how much?
Kura Oncology Inc(KURA) does not pay dividend.
Guru Commentaries on NAS:KURA
No articles.
Press Release
Articles on Kura Oncology Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers